Strides Pharma Science Limited
Bengaluru-based Strides is an integrated pharmaceutical formulations manufacturer. The company has eight manufacturing facilities, of which four are in India and one each in Singapore, Kenya, Italy and the US. Stelis is a contract development and man...
Key Metrics
EPS
-3.37
Current ratio
1.03
Debt/Equity
1.80
Debt/EBITDA
7.89
Interest coverage ratio
0.80
Operating Cashflow to total debt
0.25
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Likely improvement in leverage in FY24 due to debt repayment, reduction in CG to Stelis; Deleveraging Likely from FY25
Improved financial performance in 9MFY24; likely to be sustained in near term
Stelis to witness turnaround in near term with restructuring of CDMO business
Long-term revenue visibility remains intact despite near-term headwinds
Liquidity : Adequate
Cons
Regulatory risks
Elongated working capital cycle:
Moderate credit profile
Risk of raw material price volatility and forex fluctuation risk
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Strides Pharma Science Limited bond.
This comprehensive profile covers key factual information about Strides Pharma Science Limited. Bengaluru-based Strides is an integrated pharmaceutical formulations manufacturer. The company has eight manufacturing facilities, of which four are in India and one each in Singapore, Kenya, Italy and the US. Stelis is a contract development and manufacturing organisation partner for the global biopharmaceutical industry, offering solutions for developing and commercialising biologics, biosimilars, and vaccines. Stelis is an associate company of Strides (held 31.12% stake as on 31 March 2023) EPS in Mar-2024 was -3.37. Current ratio in Mar-2024 was 1.03. Debt/Equity in Mar-2024 was 1.80. Debt/EBITDA in Mar-2024 was 7.89. Interest coverage ratio in Mar-2024 was 0.80. Operating Cashflow to total debt in Mar-2024 was 0.25. Total revenue for Mar-2025(E) was ₹4420.51. Net income for Mar-2025(E) stood at ₹-291.16. Total assets as of Mar-2024 were ₹5,799.41. Operating cash flow for Mar-2024 was ₹701.07. The company’s borrowing relationships include Axis Bank Limited (₹N/A Cr), ICICI Bank Limited (₹N/A Cr), IDFC First Bank Limited (₹N/A Cr), Induslnd Bank Limited (₹N/A Cr), RBL Bank Limited (₹N/A Cr), State Bank of India (₹N/A Cr), Yes Bank Limited (₹N/A Cr), Unallocated (₹N/A Cr), ICICI Bank Limited (₹N/A Cr), IDFC First Bank Limited (₹N/A Cr), Induslnd Bank Limited (₹N/A Cr), RBL Bank Limited (₹N/A Cr), State Bank of India (₹N/A Cr), Yes Bank Limited (₹N/A Cr), Aditya Birla Finance Limited (₹N/A Cr), Karnataka Bank Limited (₹N/A Cr), Union Bank of India (₹N/A Cr), Yes Bank Limited (₹N/A Cr). Peers and comparison entities consist of Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, Mankind Pharma Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Likely improvement in leverage in FY24 due to debt repayment, reduction in CG to Stelis; Deleveraging Likely from FY25; Improved financial performance in 9MFY24; likely to be sustained in near term; Stelis to witness turnaround in near term with restructuring of CDMO business; Long-term revenue visibility remains intact despite near-term headwinds; Liquidity : Adequate. Key risks include: Regulatory risks; Elongated working capital cycle:; Moderate credit profile; Risk of raw material price volatility and forex fluctuation risk. Leadership team details include Aditya Kumar (Executive Director), Ameet Hariani (Independent Director), Amol Mehta (Chief Business Officer), Arun Kumar (Executive Chairperson), Badree Komandur (Managing Director & Group CEO), Homi Rustam Khusrokhan (Independent Director), K N Swamy (Head), Kausalya Santhanam (Independent Director), Manjula Ramamurthy (Company Secretary & Compliance Officer), PVS Ramaraju (Chief Operating Officer), Subir Chakraborty (Independent Director), Surabhi Loshali (Group Chief Human Resources Officer), Terrrence Fullem (President), Umesh Kale (Chief Quality Officer), Vikesh Kumar (Group CFO). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.